Sudhir Sinha, chief executive of InnoGenomics Technologies in New Orleans, has worked on a lengthy list projects over his nearly 40-year career in biomedical research. He says the truly groundbreaking projects all have at least two things in common: They take time and a good deal of money to get off the ground.
“And if you are a startup that is really, truly doing research and development, you don’t have any revenue coming in,” Sinha said.